fortis-logo

AbNano™ VHH Anti-T-Cell Library Data Pack

Accelerate your T-cell target discovery with a semi-synthetic, immunization-derived VHH library built for phage display. Constructed from an immunized llama challenged with human CD3+ T-cells and diversified by error-prone PCR, this library delivers an estimated 7 × 108 unique clonal VHH displayed on monovalent phage. Access the full data pack to review detailed sequencing QC, validated panning results against CD3 epsilon and CD8 alpha/beta, and practical guidance for integrating the library into your existing phage display workflows.

What You Get Inside

  • Product overview of the AbNano VHH Anti-T-Cell Library: Construction from an immunized llama using human CD3+ T-cells as the immunogen, diversification by error-prone PCR across four sublibraries, and delivery as phage-displayed, monovalent VHH (catalog # L760-100).

  • Detailed sequencing QC: V-gene usage (99.98% IGHV3), CDR3 length distribution, cluster density and frequency analysis, and position-specific weight matrices for CDR1, CDR2, and CDR3 — all generated from 1.31 million long-read NGS reads.

  • Application data: Representative panning campaigns against CD3 epsilon and CD8 alpha/beta heterodimer, including clonal screening hit rates, unique binder counts, and EC50 binding curves with affinities in the nanomolar range.

  • Practical product information: Physical characteristics (titer, volume, buffer, storage), phagemid backbone (pADL-20c), representative VHH framework map, and sequencing primer locations for NGS and Sanger workflows.

AbNano VHH Anti-T-Cell Library Data Pack L760-100 data pack, a phage display VHH library resource from Abcore, a Fortis Life Sciences brand

Who Would Benefit

  • Antibody discovery teams pursuing VHH binders against T-cell surface markers for therapeutic, diagnostic, or research applications, including phage display, CAR-T, and bispecific formats.
  • Scientists evaluating immunized versus naïve or synthetic VHH library strategies and seeking validated panning data on clinically relevant T-cell targets such as CD3 and CD8.​​​​
  • Biotech and pharma groups needing a well-characterized, immunization-derived starting library with documented QC, sequencing data, and demonstrated nanomolar-affinity binder output.

Download The Data Pack Here